Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

Polina Putrik; Sofia Ramiro; Tore K Kvien; Tuulikki Sokka; Till Uhlig; Annelies Boonen; on behalf of Equity in Clinical Eligibility Criteria for RA treatment Working Group; Merete Lund Hetland

doi:10.1136/annrheumdis-2013-203819

Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

Polina Putrik, Sofia Ramiro, Tore K Kvien, Tuulikki Sokka, Till Uhlig, Annelies Boonen, on behalf of Equity in Clinical Eligibility Criteria for RA treatment Working Group, Merete Lund Hetland

Afdeling for Rygkirurgi, Led- og Bindevævssygdomme

81 Citationer (Scopus)

Abstrakt

To explore criteria regulating treatment with reimbursed biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) across Europe and to relate criteria to indicators of national socioeconomic welfare.

Originalsprog	Engelsk
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	73
Sider (fra-til)	2010-2021
ISSN	0003-4967
DOI	https://doi.org/10.1136/annrheumdis-2013-203819
Status	Udgivet - 2014

Adgang til dokumentet

10.1136/annrheumdis-2013-203819

Citationsformater

Putrik, P., Ramiro, S., Kvien, T. K., Sokka, T., Uhlig, T., Boonen, A., on behalf of Equity in Clinical Eligibility Criteria for RA treatment Working Group, & Hetland, M. L. (2014). Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? Annals of the Rheumatic Diseases, 73, 2010-2021. https://doi.org/10.1136/annrheumdis-2013-203819

Putrik, P, Ramiro, S, Kvien, TK, Sokka, T, Uhlig, T, Boonen, A, on behalf of Equity in Clinical Eligibility Criteria for RA treatment Working Group & Hetland, ML 2014, 'Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?', Annals of the Rheumatic Diseases, bind 73, s. 2010-2021. https://doi.org/10.1136/annrheumdis-2013-203819

@article{b33d9cc73ee244d3a6d230943db8832c,

title = "Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?",

abstract = "To explore criteria regulating treatment with reimbursed biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) across Europe and to relate criteria to indicators of national socioeconomic welfare.",

author = "Polina Putrik and Sofia Ramiro and Kvien, {Tore K} and Tuulikki Sokka and Till Uhlig and Annelies Boonen and {on behalf of Equity in Clinical Eligibility Criteria for RA treatment Working Group} and Hetland, {Merete Lund}",

note = "Merete Hetland er medlem af denne gruppe",

year = "2014",

doi = "10.1136/annrheumdis-2013-203819",

language = "English",

volume = "73",

pages = "2010--2021",

journal = "Annals of the Rheumatic Diseases",